Photo of Sheena Wang

With a master’s degree in biotechnology by Johns Hopkins, and a bachelor of science from the University of Western Ontario with an honors double major in genetics and cell biology, Sheena Wang brings a background in both law and science to her role, integrating both in support of the firm’s IP practice and clients.

Last week, Coherus BioSciences, Inc. (“Coherus”) announced that the United States Food and Drug Administration (“FDA”) approved YUSIMRY™, an adalimumab biosimilar. YUSIMRY™ is a tumor necrosis factor blocker approved as a subcutaneous formulation. It is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. This is